Business Wire - November 21, 2002
BST is a life science biotechnology corporation dedicated to the research and development of innovative dietary supplements that address the effects of epidemic viral infections. BST is currently developing a product that addresses the needs of people with catabolic caexiea, commonly referred to as "wasting syndrome" related to diseases such as HIV/AIDS, Hepatitis and Cancer. This product is intended to be eligible for insurance reimbursement, targeting Medicaid populations.
Before joining BST, Leibtag was Chief Operating Officer of Canadian Prostate Centre Inc. He was instrumental in leading the company through medical device Phase I and Phase II clinical trials regarding a new therapy for the treatment of prostate cancer. He brings broad experience in international marketing and manufacturing. He is a graduate of the University of Western Ontario.
Randy Lebow, President of Innovative Technology Acquisition Corporation, said: "We are pleased to have Stephen Leibtag on board as President of BST. He brings a wealth of executive management and product development experience necessary to move this Company forward. I believe his impressive track record for developing businesses and products will be a critical asset to BST's worldwide success and growth."
About BioSource Therapeutics, Inc. and Innovative Technology Acquisition Corp.
BioSource Therapeutics, Inc. is a research and development company that brings the latest cutting-edge bio-technologies together to create nutraceutical products that provide nutritional supplement solutions for people with debilitating, chronic diseases. BST is pioneering in the emerging scientific field of nutritional supplements to support traditional medical treatments and therapies.
Innovative Technology Acquisition Corporation identifies and acquires new and innovative nutraceutical products and dietary supplement companies with promising growth potential.
Statements made in this news release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of the Company's patent portfolio. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results such as, but not limited to: the ability of the Company to raise necessary capital; to attract and retain effective management; or the failure of third-party contractors to perform their contractual obligations. Prospective investors are also referred to other risks identified from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission. These statements have not been evaluated by the Food and Drug Administration. Products described herein are not intended to diagnose, treat, cure or prevent any disease.
CONTACT: Gemini Integrated Financial Services, Fort Lauderdale, Fla.
Jonathan Leinwand, 954/563-1583
SOURCE: Innovative Technology Acquisition Corporation
021121
BW021115
Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .